aftin-4: increases production of amyloid-beta protein (1-42) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5289296 |
| CHEMBL ID | 1235702 |
| SCHEMBL ID | 19111944 |
| MeSH ID | M0582982 |
| Synonym |
|---|
| CHEMBL1235702 |
| (2r)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9h-purin-2-yl}amino)butan-1-ol |
| (2r)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9h-purin-2-yl}amino)-1-butanol |
| n6-methyl-(r)-roscovitine |
| bdbm10909 |
| DB04776 |
| (2r)-2-({6-[benzyl(methyl)amino]-9-(propan-2-yl)-9h-purin-2-yl}amino)butan-1-ol |
| aftin-4 |
| r-2-[6-(benzyl-methyl-amino)-9-isopropyl-9h-purin-2-ylamino]-butan-1-ol |
| (2r)-2-[[6-[benzyl(methyl)amino]-9-propan-2-ylpurin-2-yl]amino]butan-1-ol |
| 866893-90-5 |
| CS-0034791 |
| HY-111267 |
| (r)-2-((6-(benzyl(methyl)amino)-9-isopropyl-9h-purin-2-yl)amino)butan-1-ol |
| (2r)-2-({6-[benzyl(methyl)amino]-9-(1-methylethyl)-9h-purin-2-yl}amino)butan-1-ol |
| BCP29117 |
| SCHEMBL19111944 |
| aftin 4 |
| AFTIN4 , |
| BS-18191 |
| Q27095514 |
| C76827 |
| 1-butanol,2-[[9-(1-methylethyl)-6-[methyl(phenylmethyl)amino]-9h-purin-2-yl]amino]-, (2r)- |
| EX-A4242 |
| AKOS037649399 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | IC50 (µMol) | 556.6667 | 0.0040 | 2.1093 | 9.4000 | AID1796565 |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | IC50 (µMol) | 556.6667 | 0.0010 | 1.0404 | 10.0000 | AID1796565 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | IC50 (µMol) | 556.6667 | 0.0004 | 1.0444 | 10.0000 | AID1796565 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 556.6667 | 0.0003 | 1.6878 | 9.2000 | AID1796565 |
| Casein kinase I isoform alpha | Rattus norvegicus (Norway rat) | IC50 (µMol) | 556.6667 | 0.1600 | 1.0450 | 3.0000 | AID1796565 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | IC50 (µMol) | 556.6667 | 0.0002 | 1.1832 | 10.0000 | AID1796565 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | IC50 (µMol) | 556.6667 | 0.0031 | 0.7140 | 9.0120 | AID1796565 |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | IC50 (µMol) | 556.6667 | 0.0010 | 1.2898 | 10.0000 | AID1796565 |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | IC50 (µMol) | 556.6667 | 0.0040 | 2.1093 | 9.4000 | AID1796565 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1796565 | Kinase Inhibition Assay from Article 10.1074/jbc.M500805200: \\Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives.\\ | 2005 | The Journal of biological chemistry, Sep-02, Volume: 280, Issue:35 | Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. |
| AID712278 | Agonist activity at N-type Cav2.2 channel expressed in tsA201 cell assessed as calcium current by whole-cell patch clamp method | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||